Using the research developed from the laboratory by Matthew Campbell, Trinity College Dublin, we have developed unique technologies for controlled modulation of permeability at the blood brain barrier. Having the potential to revolutionise the treatment of neurological conditions allowing small molecules to enter the brain as treatment as well as allowing pathological molecules to be removed
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- junctionthx.com
- Keywords
- Digital Quality Associates.
Junction Therapeutics Questions
Junction Therapeutics's website is junctionthx.com
Junction Therapeutics's LinkedIn profile is https://www.linkedin.com/company/junction-therapeutics
Junction Therapeutics's industry is
Biotechnology Research
Junction Therapeutics's top competitors are
Radux Devices,
Let's Talk Risk!,
Sarasota Arthritis Centers,
Digital Quality Associates,
Medsix,
Quadri Pharma,
Angels Clinical Research Institute,
Sion Biotext,
Eyemind - Part Of Meyra Group,
Otsuka Pharmaceutical Companies (U.s.).
Junction Therapeutics's categories are Biotechnology Research
Junction Therapeutics's founding year is 2016
